News

W ith approximately 60% of prescription drugs coming from Europe, including major brands like Ozempic, Botox and Eliquis, ...
Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient models from Eli Lilly and Novo Nordisk.
As drug companies increasingly adopt the DTC sales model, patients will gain the ability to buy the medicines they need at ...
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
CVS Health's move to drop Eliquis comes as the insurer's pharmacy benefit manager increasingly removes drugs from its formulary, excluding 433 products in 2022, up from 417 the year before.
President Trump on Thursday sent letters to 17 of the world’s biggest drugmakers demanding that they reduce some of their U.S ...
ELIQUIS is the only oral anticoagulant with a 12- to 24-hour post surgery initiation window, which may help physicians to observe and stabilize post-surgical patients before beginning treatment.
Eliquis’ efficacy in preventing strokes proved about as good as Pradaxa’s and slightly better than Xarelto’s. Pradaxa, which like Eliquis is dosed twice daily, demonstrated superior efficacy but not ...
Results from ARISTOTLE also demonstrated that ELIQUIS was superior to warfarin for the primary safety outcome of ISTH major bleeding (p<0.001), yielding a significant relative risk reduction of 31 ...
WASHINGTON — The blood thinner Eliquis and popular diabetes treatments including Jardiance are among the first drugs that will be targeted for price negotiations in an effort to cut Medicare costs.
It was not publicly revealed at the time, but the FDA documents now show that the reason for the original 3 month extension of the PDUFA date was serious concerns about trial misconduct in China ...
<p>WASHINGTON (AP) — The blood thinner Eliquis and popular diabetes treatments including Jardiance are among the first drugs that will be targeted for price negotiations in an effort to cut ...